GRAIL's Galleri Home Receives FDA Breakthrough Designation

The U.S. Food and Drug Administration announced on Sunday that it has granted breakthrough device designation to Galleri Home, a self-administered blood test developed by GRAIL, Inc. that can screen for eight common cancer types from a single finger-prick sample collected at home. The designation accelerates the regulatory review pathway and could bring the test to market as early as the first quarter of 2027.

The test builds on GRAIL's existing Galleri multi-cancer early detection test, which requires a venous blood draw performed by a healthcare professional. The at-home version uses proprietary microfluidic technology to analyze cell-free DNA methylation patterns from approximately 100 microliters of capillary blood—roughly two drops from a standard lancet.

Which Cancers Can It Detect

According to data submitted to the FDA from the PATHFINDER HOME trial, the test demonstrated the ability to detect signals associated with eight cancer types:

The overall weighted sensitivity across all eight cancer types was 83.4%, with a specificity of 99.1%, meaning fewer than 1 in 100 cancer-free individuals would receive a false positive result. These figures are based on a 6,200-participant clinical trial conducted at 34 sites across the United States and United Kingdom.

How the Technology Works

The Galleri Home test kit is designed for simplicity. Patients receive a small box containing a lancet, a proprietary capillary blood collection card, and a prepaid return mailer. After performing a finger prick and applying the blood sample to the collection card, users mail the sample to GRAIL's CLIA-certified laboratory in Research Triangle Park, North Carolina.

"We have spent four years engineering a sample collection system that maintains DNA methylation integrity at ambient temperature for up to 14 days. That was the critical technical barrier to enabling an at-home format," said Dr. Josh Ofman, GRAIL's Chief Medical Officer.

Results are typically available within 10 business days and are delivered to the ordering physician, who then communicates findings to the patient. A positive signal triggers a recommended diagnostic workup specific to the cancer type identified.

Clinical Significance and Limitations

Oncologists have responded to the announcement with cautious optimism. Dr. Nickolas Papadopoulos, a cancer genetics researcher at Johns Hopkins, called the at-home format a potential inflection point for early detection, particularly for cancers like pancreatic and ovarian that lack established screening protocols.

However, experts caution that the test is designed as a complement to, not a replacement for, existing cancer screening methods such as mammography, colonoscopy, and low-dose CT scans for lung cancer. The sensitivity figures, while promising, mean that roughly 17% of cancers may not be detected by the test.

Dr. Laura Esserman, director of the UCSF Carol Franc Buck Breast Care Center, noted that the test's greatest value may lie in detecting cancers for which no routine screening currently exists, including pancreatic, ovarian, and esophageal cancers, which are often diagnosed at advanced stages.

Pricing and Access

GRAIL has not announced official pricing for Galleri Home but indicated it will be positioned below the current $949 list price of the professional Galleri test. Industry analysts at Cowen estimate a likely price point between $399 and $549 per test. The company has initiated discussions with major insurers, including UnitedHealth Group and Aetna, regarding potential coverage for individuals over age 50 or those with elevated cancer risk profiles.

Medicare coverage remains uncertain. CMS issued a national coverage determination for multi-cancer detection tests in 2025 that requires additional evidence of clinical utility—specifically, data showing that early detection via the test leads to improved survival outcomes. GRAIL said it expects to have mortality benefit data from its ongoing NHS-Galleri trial in the United Kingdom by mid-2027.

What Comes Next

With the breakthrough device designation in hand, GRAIL can now engage in more frequent and collaborative communication with FDA reviewers as it prepares its premarket approval application. The company expects to submit the application in the third quarter of 2026, with a potential approval decision by early 2027.